schliessen

Filtern

 

Bibliotheken

Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.

Previous studies in animals have demonstrated liposome-encapsulated doxorubicin (LED) has substantially less cardiac toxicity than free doxorubicin but retains antitumor activity. In a phase I clinical study of LED, the maximum tolerated dose was 90 mg/m2 and dose-limiting toxicity was considered to... Full description

Journal Title: Journal of the National Cancer Institute November 7, 1990, Vol.82(21), pp.1706-1710
Main Author: Treat, J
Other Authors: Greenspan, A , Forst, D , Sanchez, J A , Ferrans, V J , Potkul, L A , Woolley, P V , Rahman, A
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0027-8874
Link: http://search.proquest.com/docview/80092552/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest80092552
title: Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
format: Article
creator:
  • Treat, J
  • Greenspan, A
  • Forst, D
  • Sanchez, J A
  • Ferrans, V J
  • Potkul, L A
  • Woolley, P V
  • Rahman, A
subjects:
  • Adult–Drug Therapy
  • Aged–Administration & Dosage
  • Breast Neoplasms–Therapeutic Use
  • Doxorubicin–Toxicity
  • Drug Carriers–Drug Effects
  • Drug Evaluation–Drug Effects
  • Female–Drug Effects
  • Heart–Drug Effects
  • Humans–Drug Effects
  • Liposomes–Drug Effects
  • Middle Aged–Drug Effects
  • Radionuclide Ventriculography–Drug Effects
  • Drug Carriers
  • Liposomes
  • Doxorubicin
ispartof: Journal of the National Cancer Institute, November 7, 1990, Vol.82(21), pp.1706-1710
description: Previous studies in animals have demonstrated liposome-encapsulated doxorubicin (LED) has substantially less cardiac toxicity than free doxorubicin but retains antitumor activity. In a phase I clinical study of LED, the maximum tolerated dose was 90 mg/m2 and dose-limiting toxicity was considered to have been reached when granulocytopenia was produced. We used LED to treat 20 patients with advanced, measurable breast cancer. LED was given at doses of 60-75 mg/m2 every 3 weeks as an intravenous infusion. Regression of disease was objectively measured in nine patients; in five of these patients, complete regression of the index lesion occurred. The mean duration of the responses was 7 months. Hematologic toxicity consisted of grade 1-2 leukopenia in some patients. Gastrointestinal toxicity and mucositis were generally mild and tolerable. Alopecia occurred in all patients and usually was complete. Twelve patients received cumulative doses of LED of greater than 400 mg/m2 and were evaluated with radionuclide ventriculograms. In eight patients, the cumulative dose was greater than 500 mg/m2, and five had endomyocardial biopsies. Four of these biopsy results were Billingham grade 0, while one (cumulative LED dose, 750 mg/m2) showed grade 1 changes with mild myofibrillar loss and dilatation of the sarcoplasmic reticulum involving less than 5% of cardiac myocytes. Two patients had decreases in left ventricular ejection fraction. One of these patients had received a total dose of LED of 630 mg/m2 and had a decline of 13% in left ventricular ejection fraction, but had no clinical evidence of congestive heart failure and had a Billingham grade 0 endomyocardial biopsy.(ABSTRACT TRUNCATED AT 250 WORDS)
language: eng
source:
identifier: ISSN: 0027-8874
fulltext: fulltext
issn:
  • 00278874
  • 0027-8874
url: Link


@attributes
ID1426032283
RANK0.06999999
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid80092552
sourceidproquest
recordidTN_proquest80092552
sourcesystemOther
pqid80092552
display
typearticle
titleAntitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
creatorTreat, J ; Greenspan, A ; Forst, D ; Sanchez, J A ; Ferrans, V J ; Potkul, L A ; Woolley, P V ; Rahman, A
contributorTreat, J (correspondence author) ; Treat, J (record owner)
ispartofJournal of the National Cancer Institute, November 7, 1990, Vol.82(21), pp.1706-1710
identifierISSN: 0027-8874
subjectAdult–Drug Therapy ; Aged–Administration & Dosage ; Breast Neoplasms–Therapeutic Use ; Doxorubicin–Toxicity ; Drug Carriers–Drug Effects ; Drug Evaluation–Drug Effects ; Female–Drug Effects ; Heart–Drug Effects ; Humans–Drug Effects ; Liposomes–Drug Effects ; Middle Aged–Drug Effects ; Radionuclide Ventriculography–Drug Effects ; Drug Carriers ; Liposomes ; Doxorubicin
languageeng
source
descriptionPrevious studies in animals have demonstrated liposome-encapsulated doxorubicin (LED) has substantially less cardiac toxicity than free doxorubicin but retains antitumor activity. In a phase I clinical study of LED, the maximum tolerated dose was 90 mg/m2 and dose-limiting toxicity was considered to have been reached when granulocytopenia was produced. We used LED to treat 20 patients with advanced, measurable breast cancer. LED was given at doses of 60-75 mg/m2 every 3 weeks as an intravenous infusion. Regression of disease was objectively measured in nine patients; in five of these patients, complete regression of the index lesion occurred. The mean duration of the responses was 7 months. Hematologic toxicity consisted of grade 1-2 leukopenia in some patients. Gastrointestinal toxicity and mucositis were generally mild and tolerable. Alopecia occurred in all patients and usually was complete. Twelve patients received cumulative doses of LED of greater than 400 mg/m2 and were evaluated with radionuclide ventriculograms. In eight patients, the cumulative dose was greater than 500 mg/m2, and five had endomyocardial biopsies. Four of these biopsy results were Billingham grade 0, while one (cumulative LED dose, 750 mg/m2) showed grade 1 changes with mild myofibrillar loss and dilatation of the sarcoplasmic reticulum involving less than 5% of cardiac myocytes. Two patients had decreases in left ventricular ejection fraction. One of these patients had received a total dose of LED of 630 mg/m2 and had a decline of 13% in left ventricular ejection fraction, but had no clinical evidence of congestive heart failure and had a Billingham grade 0 endomyocardial biopsy.(ABSTRACT TRUNCATED AT 250 WORDS)
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/80092552/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Treat, J
1Greenspan, A
2Forst, D
3Sanchez, J A
4Ferrans, V J
5Potkul, L A
6Woolley, P V
7Rahman, A
titleAntitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
subject
0Adult–Drug Therapy
1Aged–Administration & Dosage
2Breast Neoplasms–Therapeutic Use
3Doxorubicin–Toxicity
4Drug Carriers–Drug Effects
5Drug Evaluation–Drug Effects
6Female–Drug Effects
7Heart–Drug Effects
8Humans–Drug Effects
9Liposomes–Drug Effects
10Middle Aged–Drug Effects
11Radionuclide Ventriculography–Drug Effects
12Drug Carriers
13Liposomes
14Doxorubicin
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
12Environmental Science Index (ProQuest)
13Biological Science Index (ProQuest)
14Environmental Science Collection (ProQuest)
sourceidproquest
recordidproquest80092552
issn
000278874
10027-8874
rsrctypearticle
creationdate1990
addtitleJournal of the National Cancer Institute
searchscope
01007489
11007527
21007944
31009130
410000004
510000006
610000038
710000043
810000050
910000120
1010000159
1110000198
1210000200
1310000209
1410000217
1510000234
1610000238
1710000253
1810000260
1910000270
2010000271
2110000302
2210000349
2310000350
2410000354
25proquest
scope
01007489
11007527
21007944
31009130
410000004
510000006
610000038
710000043
810000050
910000120
1010000159
1110000198
1210000200
1310000209
1410000217
1510000234
1610000238
1710000253
1810000260
1910000270
2010000271
2110000302
2210000349
2310000350
2410000354
25proquest
lsr43
01007489false
11007527false
21007944false
31009130false
410000004false
510000006false
610000038false
710000043false
810000050false
910000120false
1010000159false
1110000198false
1210000200false
1310000209false
1410000217false
1510000234false
1610000238false
1710000253false
1810000260false
1910000270false
2010000271false
2110000302false
2210000349false
2310000350false
2410000354false
contributorTreat, J
startdate19901107
enddate19901107
citationpf 1706 pt 1710 vol 82 issue 21
lsr30VSR-Enriched:[pqid, description]
sort
titleAntitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
authorTreat, J ; Greenspan, A ; Forst, D ; Sanchez, J A ; Ferrans, V J ; Potkul, L A ; Woolley, P V ; Rahman, A
creationdate19901107
lso0119901107
facets
frbrgroupid2286683649942622134
frbrtype5
newrecords20181218
languageeng
creationdate1990
topic
0Adult–Drug Therapy
1Aged–Administration & Dosage
2Breast Neoplasms–Therapeutic Use
3Doxorubicin–Toxicity
4Drug Carriers–Drug Effects
5Drug Evaluation–Drug Effects
6Female–Drug Effects
7Heart–Drug Effects
8Humans–Drug Effects
9Liposomes–Drug Effects
10Middle Aged–Drug Effects
11Radionuclide Ventriculography–Drug Effects
12Drug Carriers
13Liposomes
14Doxorubicin
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Environmental Science Index (ProQuest)
12Biological Science Index (ProQuest)
13Environmental Science Collection (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Treat, J
1Greenspan, A
2Forst, D
3Sanchez, J A
4Ferrans, V J
5Potkul, L A
6Woolley, P V
7Rahman, A
jtitleJournal of the National Cancer Institute
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Treat
1Greenspan
2Forst
3Sanchez
4Ferrans
5Potkul
6Woolley
7Rahman
aufirst
0J
1A
2D
3J A
4V J
5L A
6P V
au
0Treat, J
1Greenspan, A
2Forst, D
3Sanchez, J A
4Ferrans, V J
5Potkul, L A
6Woolley, P V
7Rahman, A
addauTreat, J
atitleAntitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
jtitleJournal of the National Cancer Institute
risdate19901107
volume82
issue21
spage1706
epage1710
pages1706-1710
issn0027-8874
formatjournal
genrearticle
ristypeJOUR
urlhttp://search.proquest.com/docview/80092552/
date1990-11-07